Self-Assessment: Immune Mediated Peripheral Neuropathies | Paradigm Clashes: Debate & Exploration in Choosing Traditional vs Novel Immunotherapeutics for MG-Immune Mediated Peripheral Neuropathies: Dr. Raja Presentation

Immune Mediated Peripheral Neuropathies: Dr. Raja Presentation

Pdf Summary

The document outlines emerging therapies in autoimmune neuropathies as presented by Shruti M. Raja, MD, MHS, for the 2024 session. Dr. Raja has disclosed financial relationships as a consultant for companies like Regeneron, Signant Health, Ocaro Pharmaceuticals, and Ovid Therapeutics.<br /><br />Key therapeutic innovations include lymphocyte-directed treatments targeting B-cells, T-cells, and BAFF proteins; complement inhibition focusing on C1s, C5, and Factor B; traditional therapies with immunoglobulins, plasma exchange, and corticosteroids; and FcRn antagonism, with drugs like Efgartigimod (FDA approved), Rozanolizumab, Batoclimab, and Nipocalimab undergoing trials. B-cell depletion therapies employ monoclonal antibodies targeting CD19 and CD20, with Rituximab, Ocrelizumab, and Inebilizumab as noted examples. T-cell depletion and BAFF modulation were also discussed with advancements in bispecific antibodies to reduce autoimmunity without hampering immune response. Complement inhibition targets the pathways involved with supplements like Riliprubart (C1s inhibitor), Eculizumab, Ravulizumab, and Zilucoplan (C5 inhibitors).<br /><br />The document stresses the importance of continued clinical trials and research in optimizing dosing regimens, comparing routes of administration, and improving patient outcomes. It also notes the significance of evaluating antibody diversity while highlighting ongoing studies, such as TAK-771, to refine these therapies.<br /><br />Feedback from attendees of this session is requested via the AANEM app to enhance future presentations. Additionally, attendees are encouraged to use the app before October 19, 2025, to record session attendance for credit acquisition, with details on self-assessment and CNCT Checkpoint courses to follow post-event.

Keywords

autoimmune neuropathies

emerging therapies

B-cell depletion

T-cell depletion

complement inhibition

FcRn antagonism

clinical trials

monoclonal antibodies

lymphocyte-directed treatments

patient outcomes